Multivariable Cox proportional hazards models of OS, EFS, GVHD, and GRFS
| . | OS . | EFS . | GRFS . | |||
|---|---|---|---|---|---|---|
| HR (95% CI) . | P value . | HR (95% CI) . | P value . | HR (95% CI) . | P value . | |
| Donor | ||||||
| MFD | 1 | 1 | 1 | |||
| MUD | 1.10 (0.62-1.95) | .8 | 1.33 (0.81-2.17) | .3 | 1.80 (1.20-2.70) | .004 |
| HID | 2.48 (1.14-5.40) | .02 | 4.29 (2.11-8.70) | <.001 | 3.67 (1.99-6.77) | <.001 |
| MMFD/MMUD | 2.03 (1.26-3.26) | .004 | 2.7 (1.83-4.12) | <.001 | 3.35 (2.37-4.74) | <.001 |
| Age at transplant (decades) | 1.66 (0.98-2.79) | .06 | 1.87 (1.18-2.95) | .007 | 1.62 (1.1-2.39) | .01 |
| Transplant indication | ||||||
| AA/BMF | 1 | 1 | 1 | |||
| AML/MDS | 4.47 (2.58-7.74) | <.001 | 3.66 (2.22-6.04) | <.001 | 2.42 (1.51-3.88) | <.001 |
| Conditioning | ||||||
| FluCy alone | 1 | 1 | 1 | |||
| FluCy + other | 1.81 (1.00-3.31) | .05 | 1.52 (0.90-2.55) | .12 | 1.59 (1.02-2.47) | .04 |
| Other | 1.51 (0.93-2.44) | .09 | 1.02 (0.64-1.62) | .9 | 1.26 (0.86-1.84) | .2 |
| Serotherapy | ||||||
| ATG | 1 | 1 | 1 | |||
| Alemtuzumab | 0.33 (0.14-0.77) | .01 | 0.62 (0.34-1.14) | .12 | 0.42 (0.23-0.74) | .003 |
| No serotherapy | 1.13 (0.63-2.05) | .7 | 0.92 (0.53-1.61) | .8 | 0.99 (0.63-1.55) | >.99 |
| TBI | ||||||
| No | 1 | 1 | 1 | |||
| Yes | 1.27 (0.74-2.17) | .4 | 1.19 (0.74-1.89) | .5 | 1.12 (0.75-1.68) | .6 |
| Ex vivo TCD | ||||||
| No | 1 | 1 | 1 | |||
| Yes | 0.76 (0.38-1.52) | .4 | 0.62 (0.33-1.16) | .14 | 0.6 (0.35-1.03) | .06 |
| . | OS . | EFS . | GRFS . | |||
|---|---|---|---|---|---|---|
| HR (95% CI) . | P value . | HR (95% CI) . | P value . | HR (95% CI) . | P value . | |
| Donor | ||||||
| MFD | 1 | 1 | 1 | |||
| MUD | 1.10 (0.62-1.95) | .8 | 1.33 (0.81-2.17) | .3 | 1.80 (1.20-2.70) | .004 |
| HID | 2.48 (1.14-5.40) | .02 | 4.29 (2.11-8.70) | <.001 | 3.67 (1.99-6.77) | <.001 |
| MMFD/MMUD | 2.03 (1.26-3.26) | .004 | 2.7 (1.83-4.12) | <.001 | 3.35 (2.37-4.74) | <.001 |
| Age at transplant (decades) | 1.66 (0.98-2.79) | .06 | 1.87 (1.18-2.95) | .007 | 1.62 (1.1-2.39) | .01 |
| Transplant indication | ||||||
| AA/BMF | 1 | 1 | 1 | |||
| AML/MDS | 4.47 (2.58-7.74) | <.001 | 3.66 (2.22-6.04) | <.001 | 2.42 (1.51-3.88) | <.001 |
| Conditioning | ||||||
| FluCy alone | 1 | 1 | 1 | |||
| FluCy + other | 1.81 (1.00-3.31) | .05 | 1.52 (0.90-2.55) | .12 | 1.59 (1.02-2.47) | .04 |
| Other | 1.51 (0.93-2.44) | .09 | 1.02 (0.64-1.62) | .9 | 1.26 (0.86-1.84) | .2 |
| Serotherapy | ||||||
| ATG | 1 | 1 | 1 | |||
| Alemtuzumab | 0.33 (0.14-0.77) | .01 | 0.62 (0.34-1.14) | .12 | 0.42 (0.23-0.74) | .003 |
| No serotherapy | 1.13 (0.63-2.05) | .7 | 0.92 (0.53-1.61) | .8 | 0.99 (0.63-1.55) | >.99 |
| TBI | ||||||
| No | 1 | 1 | 1 | |||
| Yes | 1.27 (0.74-2.17) | .4 | 1.19 (0.74-1.89) | .5 | 1.12 (0.75-1.68) | .6 |
| Ex vivo TCD | ||||||
| No | 1 | 1 | 1 | |||
| Yes | 0.76 (0.38-1.52) | .4 | 0.62 (0.33-1.16) | .14 | 0.6 (0.35-1.03) | .06 |
Patient age at transplant are in decades. Effect estimates are given with 95% CIs. Corresponding P values are calculated using the Wald test.